MA51082A - Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide - Google Patents

Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Info

Publication number
MA51082A
MA51082A MA051082A MA51082A MA51082A MA 51082 A MA51082 A MA 51082A MA 051082 A MA051082 A MA 051082A MA 51082 A MA51082 A MA 51082A MA 51082 A MA51082 A MA 51082A
Authority
MA
Morocco
Prior art keywords
indacen
hexahydro
sulfonamide
pyrazole
carbamoyl
Prior art date
Application number
MA051082A
Other languages
English (en)
Inventor
Rio Gancedo Susana Del
Angus Macleod
David Miller
Samuel Alexander Stratford
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MA51082A publication Critical patent/MA51082A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051082A 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide MA51082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound

Publications (1)

Publication Number Publication Date
MA51082A true MA51082A (fr) 2021-05-19

Family

ID=62236309

Family Applications (2)

Application Number Title Priority Date Filing Date
MA48051A MA48051B1 (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA051082A MA51082A (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA48051A MA48051B1 (fr) 2018-04-23 2019-04-23 Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Country Status (28)

Country Link
US (2) US10973803B2 (fr)
EP (2) EP3722281A1 (fr)
JP (1) JP7382958B2 (fr)
KR (1) KR20210005589A (fr)
CN (1) CN112020495B (fr)
AR (1) AR114827A1 (fr)
AU (1) AU2019257973A1 (fr)
BR (1) BR112020021650A2 (fr)
CA (1) CA3097832A1 (fr)
CY (1) CY1123260T1 (fr)
DK (1) DK3606909T3 (fr)
ES (1) ES2811228T3 (fr)
GB (1) GB201806578D0 (fr)
HR (1) HRP20201263T1 (fr)
HU (1) HUE050369T2 (fr)
LT (1) LT3606909T (fr)
MA (2) MA48051B1 (fr)
MD (1) MD3606909T2 (fr)
ME (1) ME03822B (fr)
MX (1) MX2020011196A (fr)
PL (1) PL3606909T3 (fr)
PT (1) PT3606909T (fr)
RS (1) RS60646B1 (fr)
SI (1) SI3606909T1 (fr)
SM (1) SMT202000448T1 (fr)
TW (1) TW201943704A (fr)
UY (1) UY38186A (fr)
WO (1) WO2019206871A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7163293B2 (ja) 2017-01-23 2022-10-31 ジェネンテック, インコーポレイテッド インターロイキン-1活性の阻害剤としての化学化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
WO2019008029A1 (fr) 2017-07-07 2019-01-10 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP3668601A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3668843A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
WO2019092171A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
CA3078195A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composes de sulfonamide carboxamide
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
WO2019166627A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
WO2019166633A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Dérivés de sulfonamide utilisés en tant qu'inhibiteurs de nlrp3
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759090A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
PE20211811A1 (es) 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
WO2021089769A1 (fr) 2019-11-07 2021-05-14 Inflazome Limited Traitement et prévention d'une neuroinflammation ou d'un trouble encéphalique inflammatoire
WO2021089776A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement et prévention d'un trouble cérébral traumatique
CN114641287A (zh) * 2019-11-07 2022-06-17 英夫拉索姆有限公司 神经退行性病症的治疗和预防
EP4054564A1 (fr) * 2019-11-07 2022-09-14 Inflazome Limited Traitement de troubles auto-inflammatoires
WO2021089781A1 (fr) * 2019-11-07 2021-05-14 Inflazome Limited Traitement ou prévention de troubles cérébraux psychiatriques faisant appel à l'inhibiteur de nlrp3 n-((1,2,3,4-hexahydro-s-indacène-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
WO2022023907A1 (fr) 2020-07-31 2022-02-03 Novartis Ag Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
CA2383026A1 (fr) * 1999-09-14 2001-03-22 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
US20140221340A1 (en) * 2011-09-02 2014-08-07 Kyowa Hakko Kirin Co., Ltd. Chemokine receptor activity regulator
MY193765A (en) 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Nlrp活性に関連する状態を処置するための化合物および組成物
EP3272739A1 (fr) 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
HRP20201263T1 (hr) 2021-02-05
KR20210005589A (ko) 2021-01-14
PL3606909T3 (pl) 2020-11-16
US20210315862A1 (en) 2021-10-14
JP7382958B2 (ja) 2023-11-17
CN112020495B (zh) 2024-05-17
CA3097832A1 (fr) 2019-10-31
PT3606909T (pt) 2020-07-09
SMT202000448T1 (it) 2020-09-10
JP2021522195A (ja) 2021-08-30
RS60646B1 (sr) 2020-09-30
ES2811228T3 (es) 2021-03-11
UY38186A (es) 2019-11-29
MX2020011196A (es) 2020-11-13
LT3606909T (lt) 2020-10-12
MA48051B1 (fr) 2020-08-31
AR114827A1 (es) 2020-10-21
HUE050369T2 (hu) 2020-11-30
CY1123260T1 (el) 2021-12-31
WO2019206871A1 (fr) 2019-10-31
US10973803B2 (en) 2021-04-13
ME03822B (fr) 2021-04-20
AU2019257973A1 (en) 2020-11-19
TW201943704A (zh) 2019-11-16
MD3606909T2 (ro) 2020-08-31
CN112020495A (zh) 2020-12-01
EP3606909A1 (fr) 2020-02-12
SI3606909T1 (sl) 2020-09-30
EP3606909B1 (fr) 2020-05-27
BR112020021650A2 (pt) 2021-01-26
EP3722281A1 (fr) 2020-10-14
GB201806578D0 (en) 2018-06-06
US20200237723A1 (en) 2020-07-30
DK3606909T3 (da) 2020-08-24

Similar Documents

Publication Publication Date Title
MA51082A (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
DK3986890T3 (da) Benzisoxazol-sulfonamid-derivater
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
LT3494115T (lt) N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
LT3743420T (lt) Heterociklilaminu pakeisti triazolai, kaip su rho susijusios proteinkinazės moduliatoriai
HUE057414T2 (hu) Új szulfonamid karboxamid vegyületek
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201792021A1 (ru) Ингибитор jak
EP4021896A4 (fr) Sel
EP3857899C0 (fr) Synthèse d'images
EP3837635A4 (fr) Compression d'image
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
JP1638163S (ja) 内視鏡用プロセッサ
EP3918915A4 (fr) Eau fonctionnelle
EP4046446C0 (fr) Différenciation de type de réponse d'accès aléatoire
EP3785785A4 (fr) Filtre à tamis
HUE062726T2 (hu) 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái
EP3856174A4 (fr) Inhibiteurs de hdac1, 2
DK3610783T3 (da) Billedkvalitetsbedømmelse
DK3942339T3 (da) Elektro-akustisk transducer
DK3908733T3 (da) Brøndfremgangsmåde
EP4052216C0 (fr) Processeur d'image
EP4081296C0 (fr) Composés dérivés de dihydrocyclopenta-isoquinoline-sulfonamide
EA201691265A1 (ru) Соединения агонисты gpr142